Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.68 |
| ▸ | APP | P05067 | 3/20 | 0.58 |
| ▸ | GRM5 | P41594 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CA3 | P07451 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23979323 | 0.95 | ACHE (0.62) | ACHEAPPGRM5CA12CA2 | |
| SCHEMBL4267390 | 0.88 | ACHE (0.52) | ACHEAPPGRM5CA12CA2 | |
| SCHEMBL9445826 | 0.86 | GRM5 (0.64) | ACHEAPPGRM5CA12CA2 | |
| SCHEMBL4457730 | 0.86 | GRM5 (0.64) | ACHEAPPGRM5CA12CA2 | |
| SCHEMBL14400750 | 0.86 | APP (0.74) | ACHEAPPCA12CA2CA9 | |
| SCHEMBL673609 | 0.86 | APP (0.74) | ACHEAPPCA12CA2CA9 | |
| SCHEMBL9715647 | 0.83 | GRM5 (0.61) | ACHEAPPGRM5CA12CA2 | |
| P-Cresol SCHEMBL375 | 0.83 | — | — | |
| P-Cresol SCHEMBL960690 | 0.83 | ACHE (1.00) | ACHECA12CA2CA9CA1 | |
| P-Cresol SCHEMBL9726112 | 0.83 | ACHE (1.00) | ACHECA12CA2CA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786481-B2 | Formulation and process for modulating wound healing | BioMendics, LLC (US) | 2023-10-17 | — | — | US | disclosed |
| CN-105152919-A | Compounds for the treatment of metabolic diseases | UNIV SYDDANSK | 2015-12-16 | — | — | CN | disclosed |
| CN-102137836-B | Compounds for the treatment of metabolic disorders | SYDDANSK UNIVERSITET (DK) | 2015-08-26 | — | — | CN | disclosed |
| US-8716355-B2 | Hydroxylated tolans and related compounds in the treatment of a cancer | KENT STATE UNIVERSITY (US) | 2014-05-06 | — | — | US | disclosed |
| US-8680142-B2 | Ascorbate, vitamin K3 and hydroxytolans in the treatment of cancer | KENT STATE UNIVERSITY (US) | 2014-03-25 | — | — | US | disclosed |
| US-8460576-B2 | Liquid crystal composition containing polymerizable compound and liquid crystal display element using the same | DIC CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| CN-102137836-A | Compounds for the treatment of metabolic disorders | UNIV SYDDANSK | 2011-07-27 | — | — | CN | disclosed |
| US-20110130468-A1 | HYDROXYLATED TOLANS AND RELATED COMPOUNDS IN THE TREATMENT OF A CANCER | KENT STATE UNIVERSITY (US) | 2011-06-02 | — | — | US | disclosed |
| US-6171664-B1 | TOLAN DERIVATIVES ARE USEFUL AS ELECTRO-OPTICAL DISPLAY; CHEMICAL, HEAT AND RADIATION RESISTANCE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2001-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11786481-B2 | Formulation and process for modulating wound healing | SQSTM1, ATG7, TFEB | ACHE 3582/4885APP 4010/4885GRM5 4477/4885 |
| US-20110130468-A1 | HYDROXYLATED TOLANS AND RELATED COMPOUNDS IN THE TREATMENT OF A CANCER | TKT, HAAO, TTPA | ACHE 4095/4885APP 4407/4885GRM5 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.